DR23 DataRelease

SDY15: Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis
Status: New
Description: The main objective of the Atopic Dermatitis and Vaccinia Network (ADVN) is to reduce the risk of eczema vaccinatum (EV) following smallpox vaccination. Since direct vaccination of atopic dermatitis (AD) subjects with live vaccinia virus (VV) is contraindicated due to the heightened risk of EV, a surrogate virus, yellow fever (YF) (the highly attenuated vaccine strain, 17D), was chosen. This is a live virus that can be administered transcutaneously (TC) with a bifurcated needle in a manner analogous to smallpox vaccination. In this study, AD subjects and controls will be vaccinated with the yellow fever virus (YFV) (YFV-17D) by the subcutaneous (SC) or TC route to determine: 1) whether there are quantitative differences in the antiviral immune responses elicited in these 2 distinct groups of subjects; and 2) whether the route of vaccination alters these immune responses, especially in AD subjects who may have altered cutaneous immunity. Using in-depth analysis of both innate and adaptive immunity in AD subjects and controls, an immunological signature may be identified that would aid in the screening process of individuals who might be at risk for EV. Moreover, this study will provide substantial information about normal and defective cutaneous immunity in AD subjects, which will be critical for future development of therapeutic drugs aimed at preventing or alleviating EV, as well as other more common viral skin infections.
Program/Contract:
ProgramContract
Atopic Dermatitis & Vaccinia Network (ADVN) Atopic Dermatitis and Vaccinia Network (ADVN) Clinical Studies Consort-26629c
DOI: 10.21430/M3KTJ8SA7A
Subjects: 82
Study PI, contact:
NameOrganizationSite
Jon Hanifin Oregon Health and Science University Oregon Health and Science University
Publications:
Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis.. J Allergy Clin Immunol. Feb 2014. doi: 10.1016/j.jaci.2013.10.037. Epub 2013 Dec 10. [Pubmed: 24331381]
Resources:
ClinicalTrials.gov http://clinicaltrials.gov/ct2/show/study/NCT00723489]
Assays:
Assay TypeNumber of Exp. Samples
Luminex xMAP 348
Q-PCR 405
Virus Neutralization 225
Clinical Assessments:
Rajka-Langeland Score
SDY49: Analysis of STAT mediated dendritic cell activation mechanisms with different stimuli.
Status: New
Description: Cells isolated from healthy subjects are used for the in vitro analysis of STAT mediated dendritic cell activation with different stimuli. This is preformed by measuring cell responses to interleukin or other treatments with or without siRNA inhibition of signaling pathways mediating dendritic cell maturation. Analysis of DC responses is measured with flow cytometry, siRNA inhibition, QPCR and western blots.
Program/Contract:
ProgramContract
Modeling Immunity for Biodefense Modeling Viral Immunity and Antagonism
DOI: 10.21430/M3S5MWVVTL
Subjects: 2
Study PI, contact:
NameOrganizationSite
David Braun Mount Sinai School of Medicine Mount Sinai School of Medicine
Publications:None
Resources:
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 46
Clinical Assessments:None
SDY50: Measuring the Activation Kinetics of Signaling Pathways in virus infected or cytokine treated dendritic cells.
Status: New
Description: Analysis of the activation kinetics of signaling pathways involved with dendritic cell maturation. Analysis of activation measured by the treatment of cells with cytokines, cytokine/receptor antagonists or infection with NDV, SeV or PR8 influenza. Assay methods include flow cytometry, imaging flow cytometry, ELISA, qPCR and Western blot.
Program/Contract:
ProgramContract
Modeling Immunity for Biodefense Modeling Viral Immunity and Antagonism
DOI: 10.21430/M3TLD5BC4S
Subjects: 2
Study PI, contact:
NameOrganizationSite
Joanna Gonzalez Mount Sinai School of Medicine Mount Sinai School of Medicine
Publications:None
Resources:
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 36
Clinical Assessments:None
SDY194: Innate Immune Pathways in Elderly and Immunosuppressed Populations 2011
Status: New
Description: Innate Immune Pathways in Elderly and Immunosuppressed Populations
Program/Contract:
ProgramContract
Protective Immunity in Special Populations Innate Immune Pathways in Elderly and Immunosuppressed Populations SP2 Yale
DOI: 10.21430/M32GW683ZT
Subjects: 120
Study PI, contact:
NameOrganizationSite
Erol Fikrig Yale Yale
Publications:None
Resources:
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 445
Hemagglutination Inhibition 155
Q-PCR 6
Clinical Assessments:None
SDY272: Humoral responses to Influenza vaccination in aged populations - Year 1 2011 (See companion studies SDY622 2012, SDY648 2013, SDY739 2014, SDY819 2015)
Status: New
Description: The purpose of this study was to measure the antibody responses to the Trivalent Inactivated influenza Vaccine(TIV) in young and aged subjects
Program/Contract:
ProgramContract
Protective Immunity in Special Populations Defining defects in anti-viral immunity in the aged SP2 Wistar
DOI: 10.21430/M3T9X2TDBK
Subjects: 46
Study PI, contact:
NameOrganizationSite
Hildegund Ertl The Wistar Institute The Wistar Institute
Publications:
B cell responses to the 2011/12-influenza vaccine in the aged.. Aging (Albany NY). Mar 2013. doi: - [Pubmed: 23674565]
Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans.. PLoS One. Oct 2013. doi: 10.1371/journal.pone.0077164. eCollection 2013. [Pubmed: 24155927]
Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults.. J Immunol. Oct 2014. doi: 10.4049/jimmunol.1302503. Epub 2014 Aug 29. [Pubmed: 25172499]
BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine.. Oncotarget. Aug 2015. doi: - [Pubmed: 26277622]
A shortened interval between vaccinations with the trivalent inactivated influenza vaccine increases responsiveness in the aged.. Aging (Albany NY). Dec 2015. doi: - [Pubmed: 26637961]
Resources:
H. Ertl's Laboratory http://wistar.org/lab/hildegund-cj-ertl-md]
Assays:
Assay TypeNumber of Exp. Samples
ELISA 798
Flow Cytometry 2361
Virus Neutralization 516
Clinical Assessments:None
SDY350: Mouse Study of X31 Influenza Infection
Status: New
Description: Influenza primary infection study with murine subject
Program/Contract:
ProgramContract
Modeling Immunity for Biodefense II University of Rochester Center for Biodefense Immune Modeling II
DOI: 10.21430/M3LO7MV28O
Subjects: 37
Study PI, contact:
NameOrganizationSite
Martin Zand University of Rochester Center for Biodefense Immune Modeling University of Rochester Medical Center
Publications:None
Resources:
Assays:
Assay TypeNumber of Exp. Samples
DNA microarray 132
Clinical Assessments:None
SDY396: Immune Responses to Seasonal LAIV 2011-2012 Influenza Vaccination in Humans (see companion study SDY224,SDY564)
Status: New
Description: To use system biology approaches to compare differences in immune responses to vaccine
Program/Contract:
ProgramContract
Modeling Immunity for Biodefense II University of Rochester Center for Biodefense Immune Modeling II
DOI: 10.21430/M3S7UQFBVS
Subjects: 18
Study PI, contact:
NameOrganizationSite
Hulin Wu University of Rochester Center for Biodefense Immune Modeling University of Rochester Medical Center
Martin Zand University of Rochester Center for Biodefense Immune Modeling University of Rochester Medical Center
Publications:None
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISA 642
ELISPOT 381
Flow Cytometry 1513
Hemagglutination Inhibition 693
Clinical Assessments:None
SDY564: Immune Responses to Seasonal TIV 2012-2013 Influenza Vaccination in Humans (see companion study SDY396,SDY224)
Status: New
Description: To use system biology approaches to compare differences in immune responses to vaccine
Program/Contract:
ProgramContract
Modeling Immunity for Biodefense II University of Rochester Center for Biodefense Immune Modeling II
DOI: 10.21430/M3ZLPC4WQZ
Subjects: 10
Study PI, contact:
NameOrganizationSite
Hulin Wu University of Rochester Center for Biodefense Immune Modeling University of Rochester Medical Center
Martin Zand University of Rochester Center for Biodefense Immune Modeling University of Rochester Medical Center
Publications:None
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISA 351
ELISPOT 9504
Flow Cytometry 908
Hemagglutination Inhibition 381
Clinical Assessments:None
SDY583: Immune Responses to Seasonal Influenza Vaccination in Mouse model
Status: New
Description: Seasonal influenza vaccine study with Murine subject
Program/Contract:
ProgramContract
Modeling Immunity for Biodefense II University of Rochester Center for Biodefense Immune Modeling II
DOI: 10.21430/M3FUNSCZCK
Subjects: 66
Study PI, contact:
NameOrganizationSite
Martin Zand University of Rochester Center for Biodefense Immune Modeling University of Rochester Medical Center
Mark Sangster University of Rochester Center for Biodefense Immune Modeling University of Rochester Medical Center
Publications:None
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISPOT 802
Flow Cytometry 197
Clinical Assessments:None
SDY585: 2013 Murine Vaccine with Adjuvant Study
Status: New
Description: Study of Influenza vaccine coupled with adjuvant in Murine model
Program/Contract:
ProgramContract
Modeling Immunity for Biodefense II University of Rochester Center for Biodefense Immune Modeling II
DOI: 10.21430/M3I8W54C3M
Subjects: 36
Study PI, contact:
NameOrganizationSite
Martin Zand University of Rochester Center for Biodefense Immune Modeling University of Rochester Medical Center
Publications:None
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISPOT 3564
Flow Cytometry 341
Clinical Assessments:None
SDY591: Cdiff32
Status: New
Description: 20 to 25-week old WT mice will be infected with 10^7 cfu/mouse of C. difficile by orogastric gavage. A control uninfected group will be included. The C difficile strain to use is VPI10463 (ATCC 43255).
Program/Contract:
ProgramContract
Modeling Immunity for Biodefense II Virginia Bioinformatics Institute Modeling Immunity for Biodefense Contract
DOI: 10.21430/M3T1G3YFSX
Subjects: 48
Study PI, contact:
NameOrganizationSite
Josep Bassaganya-Riera NIMML VBI
Publications:None
Resources:
MIEP http://www.modelingimmunity.org/]
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 266
Other 10
Clinical Assessments:None
SDY618: ADRN Influenza Vaccine Pilot (ADRN-03)
Status: New
Description: This is a single center, open-label, mechanistic study designed to determine the variance of the antibody response in non-atopic and ADEH- participants receiving a single dose of the 2011-2012 seasonal Fluzone Intradermal vaccine administered per label.
Program/Contract:
ProgramContract
Atopic Dermatitis Research Network (ADRN) Atopic Dermatitis Research Network (ADRN)
DOI: 10.21430/M3AFZ310EE
Subjects: 40
Study PI, contact:
NameOrganizationSite
Donald Leung National Jewish Health National Jewish Health
Publications:None
Resources:
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01518478]
Assays:None
Clinical Assessments:None
SDY619: ADRN Barrier/Immunoprofiling Exploratory Pilot Study (ADRN-04)
Status: New
Description: Atopic dermatitis, also called eczema, is a disease in which the skin is dry and scaly with severe itching. People with atopic dermatitis have defects in the skin barrier as well as defects in the immune system which fights off skin infections. People who have atopic dermatitis often have complications from viral and bacterial skin infections, such as recurring Staphylococcus aureus (S. aureus), or Staph infections. The purpose of this study is to look at how defects in the skin barrier and immune response affect risk for skin infections. The study will compare the skin barrier and immune response of people with and without atopic dermatitis in relation to whether Staph bacteria is growing on their skin.
Program/Contract:
ProgramContract
Atopic Dermatitis Research Network (ADRN) Atopic Dermatitis Research Network (ADRN)
DOI: 10.21430/M384Z5ZXPI
Subjects: 150
Study PI, contact:
NameOrganizationSite
Lisa Beck University of Rochester Medical Center University of Rochester Medical Center
Publications:
Temporal and Racial Differences Associated with Atopic Dermatitis Staphylococcusaureus and Encoded Virulence Factors.. mSphere. Dec 2016. doi: 10.1128/mSphere.00295-16 [Pubmed: 27981233]
Altered composition of epidermal lipids correlates with Staphylococcus aureus colonization status in atopic dermatitis.. Br J Dermatol. Oct 2017. doi: 10.1111/bjd.15409. Epub 2017 Sep 5. [Pubmed: 28244066]
Resources:
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02115399]
Assays:None
Clinical Assessments:None
SDY620: Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study (ADRN-05)
Status: New
Description: This is a multi-site, randomized, open label, mechanistic study designed to compare the immune response in non-atopic and AD participants receiving a single dose of the 2012-2013 seasonal Fluzone Intradermal vaccine administered per label. A secondary objective is to compare the immune response of AD participants receiving intradermal influenza vaccination to the response of AD participants receiving intramuscular influenza vaccination.
Program/Contract:
ProgramContract
Atopic Dermatitis Research Network (ADRN) Atopic Dermatitis Research Network (ADRN)
DOI: 10.21430/M3UT5M218G
Subjects: 368
Study PI, contact:
NameOrganizationSite
Donald Leung National Jewish Health National Jewish Health
Publications:
A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with atopic dermatitis.. J Allergy Clin Immunol. Jan 2017. doi: - [Pubmed: 28209343]
Resources:
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01737710]
Assays:None
Clinical Assessments:None
SDY622: Humoral responses to Influenza vaccination in aged populations - Year 2 2012 (See companion studies SDY272 2011, SDY648 2013, SDY739 2014, SDY819 2015)
Status: New
Description: The purpose of this study was to measure the B cell responses to the Trivalent Inactivated influenza Vaccine(TIV) in young and aged subjects, and measure their different B cell subsets.
Program/Contract:
ProgramContract
Protective Immunity in Special Populations Defining defects in anti-viral immunity in the aged SP2 Wistar
DOI: 10.21430/M34F1R11OM
Subjects: 63
Study PI, contact:
NameOrganizationSite
Hildegund Ertl The Wistar Institute The Wistar Institute
E. John Wherry University of Pennsylvania University of Pennsylvania
Publications:
B cell responses to the 2011/12-influenza vaccine in the aged.. Aging (Albany NY). Mar 2013. doi: - [Pubmed: 23674565]
Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans.. PLoS One. Oct 2013. doi: 10.1371/journal.pone.0077164. eCollection 2013. [Pubmed: 24155927]
Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults.. J Immunol. Oct 2014. doi: 10.4049/jimmunol.1302503. Epub 2014 Aug 29. [Pubmed: 25172499]
BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine.. Oncotarget. Aug 2015. doi: - [Pubmed: 26277622]
A shortened interval between vaccinations with the trivalent inactivated influenza vaccine increases responsiveness in the aged.. Aging (Albany NY). Dec 2015. doi: - [Pubmed: 26637961]
Resources:
H. Ertl's Laboratory http://wistar.org/lab/hildegund-cj-ertl-md]
Assays:
Assay TypeNumber of Exp. Samples
DNA microarray 132
ELISA 1134
Flow Cytometry 1130
Virus Neutralization 378
Clinical Assessments:None
SDY648: Humoral responses to Influenza vaccination in aged populations - Year 3 2013 (See companion studies SDY272 2011, SDY622 2012, SDY739 2014, SDY819 2015)
Status: New
Description: The purpose of this study was to measure the B celland T cell responses to the Trivalent Inactivated influenza Vaccine(TIV) in young and aged subjects, and measure their different B cell subsets.
Program/Contract:
ProgramContract
Protective Immunity in Special Populations Defining defects in anti-viral immunity in the aged SP2 Wistar
DOI: 10.21430/M3E3VOEDY2
Subjects: 63
Study PI, contact:
NameOrganizationSite
Hildegund Ertl The Wistar Institute The Wistar Institute
E. John Wherry University of Pennsylvania University of Pennsylvania
Publications:
B cell responses to the 2011/12-influenza vaccine in the aged.. Aging (Albany NY). Mar 2013. doi: - [Pubmed: 23674565]
Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans.. PLoS One. Oct 2013. doi: 10.1371/journal.pone.0077164. eCollection 2013. [Pubmed: 24155927]
Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults.. J Immunol. Oct 2014. doi: 10.4049/jimmunol.1302503. Epub 2014 Aug 29. [Pubmed: 25172499]
BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine.. Oncotarget. Aug 2015. doi: - [Pubmed: 26277622]
A shortened interval between vaccinations with the trivalent inactivated influenza vaccine increases responsiveness in the aged.. Aging (Albany NY). Dec 2015. doi: - [Pubmed: 26637961]
Resources:
H. Ertl's Laboratory http://wistar.org/lab/hildegund-cj-ertl-md]
Assays:
Assay TypeNumber of Exp. Samples
DNA microarray 124
ELISA 1134
Flow Cytometry 1130
Virus Neutralization 378
Clinical Assessments:None
SDY739: Humoral responses to Influenza vaccination in aged populations - Year 4 2014 (See companion studies SDY272 2011, SDY622 2012, SDY648 2013, SDY819 2015)
Status: New
Description: The purpose of this study was to measure the B celland T cell responses to the Trivalent Inactivated influenza Vaccine(TIV) in young and aged subjects, and measure their different B cell subsets.
Program/Contract:
ProgramContract
Protective Immunity in Special Populations Defining defects in anti-viral immunity in the aged SP2 Wistar
DOI: 10.21430/M352VU0YNY
Subjects: 65
Study PI, contact:
NameOrganizationSite
Hildegund Ertl The Wistar Institute The Wistar Institute
Publications:
B cell responses to the 2011/12-influenza vaccine in the aged.. Aging (Albany NY). Mar 2013. doi: - [Pubmed: 23674565]
Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans.. PLoS One. Oct 2013. doi: 10.1371/journal.pone.0077164. eCollection 2013. [Pubmed: 24155927]
Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults.. J Immunol. Oct 2014. doi: 10.4049/jimmunol.1302503. Epub 2014 Aug 29. [Pubmed: 25172499]
BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine.. Oncotarget. Aug 2015. doi: - [Pubmed: 26277622]
A shortened interval between vaccinations with the trivalent inactivated influenza vaccine increases responsiveness in the aged.. Aging (Albany NY). Dec 2015. doi: - [Pubmed: 26637961]
Resources:
H. Ertl's Laboratory http://wistar.org/lab/hildegund-cj-ertl-md]
Assays:
Assay TypeNumber of Exp. Samples
DNA microarray 126
ELISA 1134
Flow Cytometry 498
Virus Neutralization 378
Clinical Assessments:None
SDY746: Innate Immune Pathways in Elderly and Immunosuppressed Populations 2012
Status: New
Description: Innate Immune Pathways in Elderly and Immunosuppressed Populations
Program/Contract:
ProgramContract
Protective Immunity in Special Populations Innate Immune Pathways in Elderly and Immunosuppressed Populations SP2 Yale
DOI: 10.21430/M3E3ZNTJ56
Subjects: 115
Study PI, contact:
NameOrganizationSite
Erol Fikrig Yale Yale
Publications:None
Resources:
Assays:
Assay TypeNumber of Exp. Samples
Hemagglutination Inhibition 195
Clinical Assessments:None
SDY819: Humoral responses to Influenza vaccination in aged populations - Year 5 2015 (See companion studies SDY272 2011, SDY622 2012, SDY648 2013, SDY739 2014)
Status: New
Description: The purpose of this study was to measure the B cell and T cell responses to the Trivalent Inactivated influenza Vaccine(TIV) in young and aged subjects, and measure their different B cell subsets.
Program/Contract:
ProgramContract
Protective Immunity in Special Populations Defining defects in anti-viral immunity in the aged SP2 Wistar
DOI: 10.21430/M39Y58SSCH
Subjects: 45
Study PI, contact:
NameOrganizationSite
Hildegund Ertl The Wistar Institute The Wistar Institute
E. John Wherry University of Pennsylvania University of Pennsylvania
Publications:
B cell responses to the 2011/12-influenza vaccine in the aged.. Aging (Albany NY). Mar 2013. doi: - [Pubmed: 23674565]
Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans.. PLoS One. Oct 2013. doi: 10.1371/journal.pone.0077164. eCollection 2013. [Pubmed: 24155927]
Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults.. J Immunol. Oct 2014. doi: 10.4049/jimmunol.1302503. Epub 2014 Aug 29. [Pubmed: 25172499]
BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine.. Oncotarget. Aug 2015. doi: - [Pubmed: 26277622]
A shortened interval between vaccinations with the trivalent inactivated influenza vaccine increases responsiveness in the aged.. Aging (Albany NY). Dec 2015. doi: - [Pubmed: 26637961]
Resources:
H. Ertl's Laboratory http://wistar.org/lab/hildegund-cj-ertl-md]
Assays:
Assay TypeNumber of Exp. Samples
ELISA 810
Flow Cytometry 90
Virus Neutralization 270
Clinical Assessments:None
SDY873: Modeling Viral Immunity and Antagonism in Dendritic Cells
Status: New
Description: A suite of ex vivo perturbations are applied to explore DC response
Program/Contract:
ProgramContract
Modeling Immunity for Biodefense Modeling Viral Immunity and Antagonism
DOI: 10.21430/M3EXEMMV8M
Subjects: 93
Study PI, contact:
NameOrganizationSite
Stuart Sealfon MSSM MSSM
Publications:None
Resources:
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 4171
Clinical Assessments:None
SDY901: Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Status: New
Description: The success in lung cancer therapy with Programmed Death (PD)-1 blockade suggests that immune escape mechanisms contribute to lung tumor pathogenesis. We identified a correlation between Epidermal Growth Factor Receptor (EGFR) pathway activation and a signature of immunosuppression manifested by upregulation of PD-1, PD-L1, cytotoxic T lymphocyte antigen-4 (CTLA-4), and multiple tumor-promoting inflammatory cytokines. We observed decreased cytotoxic T cells and increased markers of T cell exhaustion in mouse models of EGFR-driven lung cancer. PD-1 antibody blockade improved the survival of mice with EGFR-driven adenocarcinomas by enhancing effector T cell function and lowering the levels of tumor promoting cytokines. Expression of mutant EGFR in bronchial epithelial cells induced PD-L1, and PD-L1 expression was reduced by EGFR inhibitors in non-small cell lung cancer cell lines with activated EGFR. These data suggest that oncogenic EGFR signaling remodels the tumor microenvironment to trigger immune escape, and mechanistically link treatment response to PD-1 inhibition.
Program/Contract:
ProgramContract
Enhance Applicability of Mouse Models for Translational Research (Oncology Model, OMF) Credentialing Mouse Models for Immune System Therapy Research (Oncology Model, OMF)
DOI: 10.21430/M3VRA7INN8
Subjects: 8
Study PI, contact:
NameOrganizationSite
Kwok-Kin Wong Dana Farber Cancer Institute Dana Farber Cancer Institute
Publications:
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.. Cancer Discov. Dec 2013. doi: 10.1158/2159-8290.CD-13-0310. Epub 2013 Sep 27. [Pubmed: 24078774]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 6
Clinical Assessments:None
SDY1025: APIC
Status: New
Description: This study looks to define the phenotypic characteristics of Difficult-to-Treat asthma, among 650 children between the ages of 6 to 17 years, receiving one year of guidelines-based therapy for asthma and rhinitis/rhinosinusitis.
Program/Contract:
ProgramContract
Inner City Asthma Consortium (ICAC) Inner City Asthma Consortium (ICAC)
DOI: 10.21430/M39SEUM79K
Subjects: 717
Study PI, contact:
NameOrganizationSite
William Busse University of Wisconsin-Madison University of Wisconsin-Madison
Publications:
Asthma phenotypes in inner-city children.. J Allergy Clin Immunol. Oct 2016. doi: 10.1016/j.jaci.2016.06.061. [Pubmed: 27720016]
Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents.. J Allergy Clin Immunol. Oct 2016. doi: 10.1016/j.jaci.2016.06.059. [Pubmed: 27720017]
Pathways through which asthma risk factors contribute to asthma severity in inner-city children.. J Allergy Clin Immunol. Oct 2016. doi: 10.1016/j.jaci.2016.06.060. [Pubmed: 27720018]
Obstruction phenotype as a predictor of asthma severity and instability in children.. J Allergy Clin Immunol. Nov 2017. doi: - [Pubmed: 29146272]
Expression of Corticosteroid Regulated Genes By Peripheral Blood Mononuclear Cells in Children with Asthma.. J Allergy Clin Immunol. Jul 2018. doi: - [Pubmed: 30059697]
Rhinitis in Children and Adolescents with Asthma: Ubiquitous, Difficult to Control, and Associated with Asthma Outcomes.. J Allergy Clin Immunol. Sep 2018. doi: - [Pubmed: 30213627]
Resources:
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/study/NCT01383941]
Assays:None
Clinical Assessments:
Allergen Skin Test
Body Mass Index
Composite Asthma Severity Index
Exhaled Nitric Oxide
Indoor Allergens
Ipratropium Reversibility
Methacholine Challenge
Perceived Stress Scale
Plesthymography
Rhinitis/Rhinosinusitis Diagnostic Questionnaire
Spirometry
SDY1026: BioCSI 2 (Biomarkers of Cockroach Sublingual Immunotherapy 2)
Status: New
Description: This study looks to compare two doses of glycerinated German cockroach allergenic extract versus placebo administered via the sublingual route in 99 children ages 5 to 17 years with perennial allergic rhinitis, asthma, or both. It is designed to study biomarkers of the immune response to allergen immunotherapy as well as the safety of this therapy.
Program/Contract:
ProgramContract
Inner City Asthma Consortium (ICAC) Inner City Asthma Consortium (ICAC)
DOI: 10.21430/M3LVUFRQOA
Subjects: 99
Study PI, contact:
NameOrganizationSite
Robert Wood Johns Hopkins University School of Medicine Johns Hopkins University School of Medicine
Publications:
Development of cockroach immunotherapy by the Inner-City Asthma Consortium.. J Allergy Clin Immunol. Mar 2014. doi: 10.1016/j.jaci.2013.08.047. Epub 2013 Nov 1. [Pubmed: 24184147]
Resources:
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/study/NCT01380327]
Assays:None
Clinical Assessments:None
SDY1027: Epigenetics
Status: New
Description: The study is designed to determine the relation between methylation of CpG motifs and asthma in children residing in the inner city.
Program/Contract:
ProgramContract
Inner City Asthma Consortium (ICAC) Inner City Asthma Consortium (ICAC)
DOI: 10.21430/M3SXDBHQTS
Subjects: 200
Study PI, contact:
NameOrganizationSite
David Schwartz National Jewish Health National Jewish Health
Andrew Liu National Jewish Health National Jewish Health
Herman Mitchell Rho, Inc. Rho, Inc.
Publications:
DNA methylation and childhood asthma in the inner city.. J Allergy Clin Immunol. Jul 2015. doi: 10.1016/j.jaci.2015.01.025. Epub 2015 Mar 11. [Pubmed: 25769910]
Resources:
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/study/NCT01382836]
Assays:
Assay TypeNumber of Exp. Samples
DNA methylation profiling assay 194
DNA microarray 194
Clinical Assessments:None
SDY1028: Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (PROSE)
Status: New
Description: A three-armed prospective randomized double-blind placebo-controlled trial investigating the efficacy of standard care plus 4-5 months of treatment with (a) a boost of inhaled corticosteroid therapy Flovent Diskus (fluticasone) versus (b) Xolair(omalizumab) or (c) placebo Xolair (omalizumab) and placebo Flovent Diskus (fluticasone) in reducing the exacerbations during the fall season.
Program/Contract:
ProgramContract
Inner City Asthma Consortium (ICAC) Inner City Asthma Consortium (ICAC)
DOI: 10.21430/M3HZZOS3Y5
Subjects: 513
Study PI, contact:
NameOrganizationSite
William Busse University of Wisconsin-Madison University of Wisconsin-Madison
Samuel Arbes Rho Rho
Publications:
Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.. J Allergy Clin Immunol. Dec 2015. doi: 10.1016/j.jaci.2015.09.008. Epub 2015 Oct 27. [Pubmed: 26518090]
Resources:
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/study/NCT01430403]
Assays:None
Clinical Assessments:
Asthma Control Test
Childhood Asthma Control Test
Dust Sample Lab Results
Exhaled Nitric Oxide
Spirometry
SDY1029: SCITCO (Subcutaneous Immunotherapy for Cockroach)
Status: New
Description: This is an open label single site trial of German cockroach allergenic extract administered by subcutaneous injection in 10 adults ages 18 to 55 years with perennial allergic rhinitis, asthma, or both. It is designed to study biomarkers of the immune response to allergen immunotherapy as well as the safety of this therapy.
Program/Contract:
ProgramContract
Inner City Asthma Consortium (ICAC) Inner City Asthma Consortium (ICAC)
DOI: 10.21430/M3XJ80W9FK
Subjects: 11
Study PI, contact:
NameOrganizationSite
Robert Wood Johns Hopkins University School of Medicine Johns Hopkins University School of Medicine
Publications:
Development of cockroach immunotherapy by the Inner-City Asthma Consortium.. J Allergy Clin Immunol. Mar 2014. doi: 10.1016/j.jaci.2013.08.047. Epub 2013 Nov 1. [Pubmed: 24184147]
Resources:
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/study/NCT01221285]
Assays:None
Clinical Assessments:None
SDY1100: Project 3 - Optimization experiments DCs DV2 and DV4 - CyTOF
Status: New
Description: Ex vivo infections of human monocyte derived DCs DENV2 and DENV4 analysis were performed to study the innate immune profile upon infection with those viruses using CyTOF and to elucidate the appropiated time points for future experiments.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 2 (HIPC2) Dengue Human Immunology Project Consortium (DHIPC MSSM)
DOI: 10.21430/M3JDEIXF26
Subjects: 7
Study PI, contact:
NameOrganizationSite
Ana Fernandez-Sesma Icahn School of Medicine at Mount Sinai N/A
Publications:
High-dimensional CyTOF analysis of dengue virus-infected human DCs reveals distinct viral signatures.. JCI Insight. Jul 2017. doi: 10.1172/jci.insight.92424. [Epub ahead of print] [Pubmed: 28679950]
None. None None None. doi: None [Pubmed: N/A]
Resources:
N/A N/A]
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 84
Clinical Assessments:None
SDY1108: Systemic Immunity for Cancer Immunotherapy
Status: New
Description: A systems approach reveals that engagement of systemic immunity is critical to the process of tumor rejection following immunotherapy. Using a spontaneous model of triple-negative breast cancer, we assessed immune cell dynamics across the organism during tumor rejection
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M3L410EFMQ
Subjects: 13
Study PI, contact:
NameOrganizationSite
Matthew Spitzer UCSF; Stanford University Helen Diller Comprehensive Cancer Center, Dept. of Pathology, Dept. of Microbiology and Immunology
Garry Nolan Stanford University Department of Microbiology and Immunology
Edgar Engleman Stanford University Department of Pathology
Publications:
Systemic Immunity Is Required for Effective Cancer Immunotherapy.. Cell. Jan 2017. doi: 10.1016/j.cell.2016.12.022. Epub 2017 Jan 19. [Pubmed: 28111070]
Resources:
Cytobank data https://github.com/SpitzerLab/Modeling_Effective_Cancer_Immunotherapy]
Github StatisticalScaffoldTool https://github.com/SpitzerLab/statisticalScaffold]
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 130
Clinical Assessments:None
SDY1115: Comparative analysis of neonatal and adult immune responses after in vitro rhinovirus stimulation
Status: New
Description: Rhinovirus infections during infancy account for the majority of respiratory illness health care utilization and are an associated risk factor for subsequent development of allergic asthma. Neonatal type I interferon production is diminished compared to adults after stimulation with TLR agonists. However, broad profiling of immune cell responses to infectious rhinovirus has not been undertaken and we hypothesized that additional immune differences can be identified in neonates.
Program/Contract:
ProgramContract
Asthma and Allergic Diseases Cooperative Research Centers 1 (AADCRC1) Mechanisms and Enviromental Determinants of Rhinovirus Illness Severity (AADCRC1)
DOI: 10.21430/M3IR2J7XWW
Subjects: 17
Study PI, contact:
NameOrganizationSite
Christine Seroogy Department of Pediatrics, University of Wisconsin School of Medicine and Public Health University of Wisconsin
Publications:
Neonatal immune response to rhinovirus A16 has diminished dendritic cell function and increased B cell activation.. PLoS One. Oct 2017. doi: 10.1371/journal.pone.0180664. eCollection 2017. [Pubmed: 29045416]
Resources:
Division of Allergy and Immunology https://www.medicine.wisc.edu/people-search/people/staff/168/LEMANSKE_ROBERT_F]
Division of Rheumatology https://www.medicine.wisc.edu/rheumatology/rheumatologymain]
Department of Pediatrics https://www.pediatrics.wisc.edu/]
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 56
Clinical Assessments:None
SDY1149: Project 3 - Optimization experiments DCs DV2 and DV4 - MBAA
Status: New
Description: Ex vivo infections of human monocyte derived DCs DENV2 (16681) and DENV4 (Indonesia/1976/1036) analysis were performed to study the innate immune profile upon infection usin a multiplexed beads array assay (MBAA) with those viruses and to elucidate the appropiated time points for future experiments.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 2 (HIPC2) Dengue Human Immunology Project Consortium (DHIPC MSSM)
DOI: 10.21430/M3C546VF92
Subjects: 7
Study PI, contact:
NameOrganizationSite
Ana Fernandez-Sesma Icahn School of Medicine at Mount Sinai N/A
Publications:
High-dimensional CyTOF analysis of dengue virus-infected human DCs reveals distinct viral signatures.. JCI Insight. Jul 2017. doi: 10.1172/jci.insight.92424. [Epub ahead of print] [Pubmed: 28679950]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
Luminex xMAP 2100
Other 84
Clinical Assessments:None
SDY1152: Phosphorylation profiles of ERK, p38, MAPKs in DCs in response to different pathogenic stimuli
Status: New
Description: 2 different stimuli were used to activated DCs LPS and Curdlan. A time course experiment was conducted for 2 hr to measure the phosphorylation profiles of MAPKs, ERK1/2 and p38.
Program/Contract:
ProgramContract
Modeling Immunity for Biodefense Modeling Viral Immunity and Antagonism
DOI: 10.21430/M3N3RFL2E5
Subjects: 2
Study PI, contact:
NameOrganizationSite
S Patil Mount Sinai School of Medicine MSSM
Publications:None
Resources:
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 37
Clinical Assessments:None
SDY1153: Induction of maturation Marker after combinatorial TNFa and IFNb treatment
Status: New
Description: Explore combinatorial TNFa and IFNb treatment of DCs
Program/Contract:
ProgramContract
Modeling Immunity for Biodefense Modeling Viral Immunity and Antagonism
DOI: 10.21430/M35IWA4GOQ
Subjects: 2
Study PI, contact:
NameOrganizationSite
NC Fellini Mount Sinai School of Medicine MSSM
Publications:None
Resources:
Assays:
Assay TypeNumber of Exp. Samples
DNA microarray 21
Flow Cytometry 54
Clinical Assessments:None
SDY1154: siRNA knock down of RIG-I and TBK1 in DCs
Status: New
Description: DCs were transfected with RIG-I or TBK1 targeting siRNA and infected with NDV 24h post-transfectio
Program/Contract:
ProgramContract
Modeling Immunity for Biodefense Modeling Viral Immunity and Antagonism
DOI: 10.21430/M3WMFFH6SY
Subjects: 2
Study PI, contact:
NameOrganizationSite
R Bowles Mount Sinai School of Medicine MSSM
Publications:None
Resources:
Assays:
Assay TypeNumber of Exp. Samples
Immunoblot 14
Clinical Assessments:None
SDY1155: RNA-Seq and miRNA-Seq of Human Placenta
Status: New
Description: RNA sequencing was performed with the primary goal of discovering key placental villous trophoblast(VT) and decidual basalis(DB) transcripts differentially expressed in intra-amniotic infection (IAI)-induced pretrem birth (PTB)
Program/Contract:
ProgramContract
March of Dimes March of Dimes Human Microbiome
DOI: 10.21430/M34I5YT3K9
Subjects: 15
Study PI, contact:
NameOrganizationSite
William Ackerman The Ohio State College of Medicine, Columbus, OH The Ohio State University Comprehensive Cancer Center
Publications:
Comprehensive RNA profiling of villous trophoblast and decidua basalis in pregnancies complicated by preterm birth following intra-amniotic infection.. Placenta. Aug 2016. doi: 10.1016/j.placenta.2016.05.010. Epub 2016 May 30. [Pubmed: 27452435]
Resources:
March of Dimes Prematurity Research Center Ohio Collaborative http://prematurityresearch.org/ohiocollaborative/]
Eunice Kenedy Shriver National Insititute of Child Health and Human Development, NICHD RO1-HD084628 https://projectreporter.nih.gov/project_info_details.cfm?aid=8947210&icde=35731890]
Assays:
Assay TypeNumber of Exp. Samples
RNA sequencing 60
Clinical Assessments:
Medical History
Placenta Histology
Pregnancy Panel
SDY1157: Immune response throughout human pregnancy
Status: New
Description: The phenotype and intracellular signaling activities of all major innate and adaptive immune cells were simultaneously quantified in serial whole-blood samples throughout pregnancy. Three sets of data were generated by quantifying the abundances of peripheral immune cell sub-sets, capturing endogenous intracellular signaling activities, and determining the capacity of immune cell subsets to respond to stimulation with receptor-specific ligands. The csEN algorithm was adapted from the Elastic Net (EN) regularized regression method and accounts for the influence of previous biological knowledge of receptor-specific signal transduction on the generation of single-cell mass cytometry data. This algorithm allowed to infer a model of interrelated immune features that accurately predicts the timing of immunological adaptations over the entire course of a term pregnancy.
Program/Contract:
ProgramContract
March of Dimes March of Dimes Human Microbiome
DOI: 10.21430/M3OV4WX72N
Subjects: 28
Study PI, contact:
NameOrganizationSite
Brice Gaudilliere Stanford University School of Medicine Department of Anesthesiology, Perioperative and Pain Medicine
Publications:
An immune clock of human pregnancy.. Sci Immunol. Sep 2017. doi: 10.1126/sciimmunol.aan2946. [Pubmed: 28864494]
Resources:
Training cohort CyTOF data http://flowrepository.org/id/FR-FCM-ZY3Q]
Validation cohort CyTOF data http://flowrepository.org/id/FR-FCM-ZY3R]
March of Dimes Prematurity Research Center at Stanford University http://prematurity.stanford.edu/]
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 448
Clinical Assessments:
Medical History
Physical Exam
Pregnancy Panel
SDY1164: Vaginal microbial signature for preterm birth
Status: New
Description: Recent studies about association between maternal vaginal microbiota and risks for preterm birth (PTB) conflicted along similar lines: Caucasian and Asian women cohorts showed associations between PTB and low Lactobacillus vaginal communities (BV-like) while no significant association with PTB was detected in cohorts of African-American women. This study compares two new larger cohorts of women at low and high risk for PTB, addressing two challenges: (i) low power resulting from the combination of small study populations (30?91 pregnant women), the many taxa measured by metabarcoding, and the absence of initial hypotheses more specific than some difference between preterm and term gestations; and (ii) insufficient understanding of population-specific factors that might modulate the PTB?microbiota association.
Program/Contract:
ProgramContract
March of Dimes March of Dimes Human Microbiome
DOI: 10.21430/M37W3869AH
Subjects: 136
Study PI, contact:
NameOrganizationSite
David Relman March of Dimes Prematurity Research Center at Stanford University School of Medicine March of Dimes Prematurity Research Center at Stanford University School of Medicine
Publications:
Replication and refinement of a vaginal microbial signature of preterm birth in two racially distinct cohorts of US women.. Proc Natl Acad Sci U S A. Aug 2017. doi: - [Pubmed: 28847941]
Resources:
March of Dimes Prematurity Research Center at Stanford University http://prematurity.stanford.edu/]
SRA ? Raw sequencing data https://www.ncbi.nlm.nih.gov/sra/SRP115697]
Stanford Digital Repository - Sequence table and R scripts for analysis workflow https://purl.stanford.edu/yb681vm1809]
Assays:
Assay TypeNumber of Exp. Samples
16S rRNA gene sequencing 2367
Clinical Assessments:
Pregnancy Delivery
SDY80: Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines
Status: Updated
Description: The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.
Program/Contract:
ProgramContract
NIH Center for Human Immunology, Autoimmunity and Inflammation (CHI) Center for Human Immunology, Autoimmunity and Inflammation
DOI: 10.21430/M3STAI2V6T
Subjects: 64
Study PI, contact:
NameOrganizationSite
John Tsang NIH NIH
Publications:
Global analyses of human immune variation reveal baseline predictors of postvaccination responses.. Cell. Apr 2014. doi: 10.1016/j.cell.2014.03.031. [Pubmed: 24725414]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISPOT 227
Flow Cytometry 1225
Transcription profiling by array 301
Virus Neutralization 564
Clinical Assessments:None
SDY180: Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine
Status: Updated
Description: Systems immunology approaches were employed to investigate innate and adaptive immune responses to influenza and pneumococcal vaccines. These two non-live vaccines show different magnitudes of transcriptional responses at different time points af- ter vaccination. Software solutions were developed to explore correlates of vaccine efficacy measured as antibody titers at day 28. These enabled a further dissection of transcriptional responses. Thus, the innate response, measured within hours in the peripheral blood, was dominated by an interferon transcriptional signature after influenza vaccination and by an inflammation signature after pneumo- coccal vaccination. Day 7 plasmablast responses induced by both vaccines was more pronounced after pneumococcal vaccination. Together, these results suggest that comparing global immune responses elicited by different vaccines will be critical to our understanding of the immune mechanisms underpinning successful vaccination.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Systems Analysis Vaccine Responses in Healthy and Hyporesponsive Humans
DOI: 10.21430/M3I44H8R17
Subjects: 46
Study PI, contact:
NameOrganizationSite
A. Karolina Palucka Baylor Reasearch Institute Baylor Reasearch Institute
Publications:
Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines.. Immunity. Apr 2013. doi: 10.1016/j.immuni.2012.12.008. [Pubmed: 23601689]
Resources:
Gene Expression Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30101]
Assays:
Assay TypeNumber of Exp. Samples
DNA microarray 542
Flow Cytometry 2208
Hemagglutination Inhibition 66
Luminex xMAP 229
Nanostring 18
Transcription profiling by array 161
Virus Neutralization 89
Clinical Assessments:None
SDY671: Knechtle ITN013ST: Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
Status: Updated
Description: This study will evaluate the effects of intravenous (IV) alemtuzumab and oral sirolimus and tacrolimus after kidney transplantation. The study will also evaluate this regimen's potential to allow eventual discontinuation of components of long-term immunosuppressive therapy. Study duration will be 4 years. Participants will undergo kidney transplantation on Day 0, receive IV doses of alemtuzumab, acetaminophen, and diphenhydramine on Days 0, 1, and 2, as well as methylprednisolone on Day 0. Patients will receive up to 10 days of valganciclovir or acyclovir post transplant. Daily oral doses of tacrolimus will contiue for 60 days and sirolimus daily by mouth for at least 12 months after transplant. Participants will take sulfamethoxazole-trimethoprim 3 times a week, valganciclovir or acyclovir for up to 10 days post-transplant, and clotrimazole or nystatin by mouth for at least 3 months post-transplant. Sixty-to study visits are planned to be spread out over 4 years post transplant. Sirolimus withdrawal process will occur over a minimum of 3 months at an approximate rate of 33% of the pre-withdrawal dose per month. Participants eligible for sirolimus withdrawal will undergo several kidney biopsies, including one 2 weeks prior to the start of withdrawal, 6 and 12 months after completion of withdrawal, 1 year after study enrollment, and annually thereafter.
Program/Contract:
ProgramContract
ITN: Collaborative Network for Clinical Research on Immune Tolerance Network Immune Tolerance Network
DOI: 10.21430/M38BB6XTX9
Subjects: 20
Study PI, contact:
NameOrganizationSite
Stuart Knechtle Emory University Immune Tolerance Network
Arjang Djamali University of Wisconsin, Madison Immune Tolerance Network
Publications:
Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring.. Am J Transplant. May 2009. doi: 10.1111/j.1600-6143.2009.02581.x. Epub 2009 Mar 16. [Pubmed: 19344431]
Longitudinal studies of a B cell-derived signature of tolerance in renal transplant recipients.. Am J Transplant. Nov 2015. doi: 10.1111/ajt.13480. Epub 2015 Oct 13. [Pubmed: 26461968]
Resources:
Clinicaltrials.gov https://www.clinicaltrials.gov/ct2/show/record/NCT00078559]
Immune Tolerance Network Trialshare https://www.itntrialshare.org]
Assays:None
Clinical Assessments:
Overall_Outcome_Data
SDY775: Evaluating differences between healthy placental microbiome and contamination control sample microbiomes
Status: Updated
Description: Placental samples from healthy deliveries were compared to an extensive set of bacterial contamination controls as well as to oral and vaginal samples from the same women. This control study was unable to distinguish bacterial species and abundance between placental and contamination control samples
Program/Contract:
ProgramContract
March of Dimes March of Dimes Human Microbiome
DOI: 10.21430/M3PZM1ERD2
Subjects: 7
Study PI, contact:
NameOrganizationSite
Frederic Bushman University of Pennsylvania School of Medicine University of Pennsylvania School of Medicine
Publications:
Comparison of placenta samples with contamination controls does not provide evidence for a distinct placenta microbiota.. Microbiome. Jun 2016. doi: 10.1186/s40168-016-0172-3. [Pubmed: 27338728]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
16S rRNA gene sequencing 69
Q-PCR 69
Clinical Assessments:None
Back to top